Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208(b)(1)

Jan Patterson, M.D.

Committee: Anti-Infective Drugs Advisory Committee

Meeting Date: March 6, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to New Drug Application (NDA) 21-572/S-008, Cubicin (daptomycin for injection 500 mg/vial), manufactured for Cubist Pharmaceuticals by Integrated Commercialization Solutions, for the proposed indication for the treatment of Staphylococcus aureus bacteremia, including those with known or suspected endocarditis caused by methicillin-susceptible and methicillin-resistant strains, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(1).

Type of Interest	**Nature**	**Magnitude**
Spouse's Unrelated Consulting/Advisory Board	Two Competing Firms	Less than $10,001 per year, per firm
Spouse's Unrelated Speaker's Bureau	Two Competing Firms	From $10,001 to $50,000 per year, per firm

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

//S// 1/27/06

Signature of SGE Date